Ida Colantonio

Cuneo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Predictors of duration of hospital stay for cancer patients admitted due to medical causes: A quality-improvement evaluation.

Predictors of duration of hospital stay for cancer patients admitted due to medical causes: A quality-improvement evaluation.

Journal: Tumori

Published: October 18, 2025

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 12, 2025

Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.

Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.

Journal: Journal for immunotherapy of cancer

Published: April 18, 2025

Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study.

Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study.

Journal: ESMO open

Published: March 05, 2025

Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group.

Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group.

Journal: Critical reviews in oncology/hematology

Published: December 07, 2024

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 06, 2024

Patients with cancer and hospital admissions: disease trajectory and strategic choices.

Patients with cancer and hospital admissions: disease trajectory and strategic choices.

Journal: BMJ supportive & palliative care

Published: August 25, 2023

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 28, 2022

A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.

A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.

Journal: Future oncology (London, England)

Published: January 24, 2022

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 14, 2021

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).

Journal: British journal of cancer

Published: May 20, 2021

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.

Journal: Journal of clinical pathology

Published: December 12, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026